Teva Pharmaceutical Industries Limited (NYSE:TEVA) Downgraded by Wells Fargo & Company

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was downgraded by investment analysts at Wells Fargo & Company to a “market perform” rating in a research report issued on Thursday, November 2nd, The Fly reports. They currently have a $11.36 price objective on the stock, down from their previous price objective of $17.00. Wells Fargo & Company’s price target suggests a potential downside of 14.78% from the company’s current price.

A number of other brokerages have also issued reports on TEVA. BidaskClub upgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a research note on Wednesday, July 5th. Jefferies Group LLC reiterated a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Tuesday, July 25th. Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 price objective on the stock in a research note on Monday, July 24th. Maxim Group reiterated a “hold” rating and set a $35.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, July 13th. Finally, Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Seven investment analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $21.88.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up $0.25 during trading on Thursday, hitting $13.33. 14,433,130 shares of the stock were exchanged, compared to its average volume of 15,453,723. The firm has a market cap of $13,820.00, a price-to-earnings ratio of 3.20 and a beta of 0.52. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries Limited has a 1-year low of $10.85 and a 1-year high of $38.69.

ILLEGAL ACTIVITY WARNING: “Teva Pharmaceutical Industries Limited (NYSE:TEVA) Downgraded by Wells Fargo & Company” was published by BBNS and is the sole property of of BBNS. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://baseballnewssource.com/markets/teva-pharmaceutical-industries-limited-teva-cut-to-market-perform-at-wells-fargo-company/1751339.html.

Large investors have recently bought and sold shares of the stock. San Francisco Sentry Investment Group CA acquired a new position in Teva Pharmaceutical Industries Limited in the 2nd quarter valued at $106,000. Kistler Tiffany Companies LLC grew its position in Teva Pharmaceutical Industries Limited by 74.7% in the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after purchasing an additional 1,571 shares during the last quarter. Bronfman E.L. Rothschild L.P. grew its position in Teva Pharmaceutical Industries Limited by 2.6% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after purchasing an additional 94 shares during the last quarter. Cutler Capital Management LLC acquired a new stake in Teva Pharmaceutical Industries Limited in the 2nd quarter worth $133,000. Finally, Shelter Mutual Insurance Co acquired a new stake in Teva Pharmaceutical Industries Limited in the 2nd quarter worth $133,000. Institutional investors and hedge funds own 52.29% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

The Fly

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.